Summary
89%
|
Pharmacokinetic
|
0% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alimemazin | |||||||||||
| Scores | -6% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
QT time prolongation
| |||||||||||
|
Anticholinergic effects
| |||||||||||
|
Serotonergic effects
| |||||||||||
|
Adverse drug events
|
-5% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukopenia | |||||||||||
| Hypotension | |||||||||||
| Photosensitivity | |||||||||||
Variants ✨
For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Intended use
Alimemazine (also known as trimeprazine) is still used in some countries to prevent and relieve allergic conditions that cause itching and urticaria (itching with a vesicular rash). It is also used as a sedative and against nausea. It is taken orally as a tablet, juice, or drops. Alimemazin is used as an antihistamine, but its structure is also a neuroleptically effective phenothiazine. It binds to the histamine H1 receptors in the gastrointestinal tract, the skin, the airways and the blood vessels and thus prevents the occurrence of allergic symptoms. In addition, it has a sedative (calming) effect and works against nausea and vomiting.
Pharmacokinetics
-0%
| ∑ Exposurea | ali | |
|---|---|---|
| Alimemazin | 1 |
Symbol (a): x-fold change in AUC
Legend (n.a.): Information not available
Legend (n.a.): Information not available
Since only alimemazin was entered without any further substances, no pharmacokinetic interactions can be detected.
Rating:
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability, half-life, and volume of distribution of alimemazin are unknown to us.
Serotonergic effects
-0%
| Scores | ∑ Points | ali |
|---|---|---|
| Serotonergic Effects a | 0 | Ø |
Symbol (a): Increased risk from 5 points.
Rating: According to our knowledge, alimemazin does not increase serotonergic activity.
Anticholinergic effects
-5%
| Scores | ∑ Points | ali |
|---|---|---|
| Kiesel b | 2 | ++ |
Symbol (b): Increased risk from 3 points.
Recommendation: As a precaution, attention should be paid to anticholinergic symptoms, especially after increasing the dose and at doses in the upper therapeutic range.
Rating: Alimemazin modulates the anticholinergic system to a moderate extent. The risk of anticholinergic syndrome with this medication is rather low if the dosage is in the usual range.
QT time prolongation
-1%
| Scores | ∑ Points | ali |
|---|---|---|
| RISK-PATH c | 0.5 | ++ |
Symbol (c): Increased risk from 10 points.
Alimemazin can potentially increase QT time, but we do not know about torsades de pointes arrhythmias.
General adverse effects
-5%
| Side effects | ∑ frequency | ali |
|---|---|---|
| Leukopenia | 30.0 % | 30.0 |
| Hypotension | 1.0 % | + |
| Photosensitivity | 1.0 % | + |
| Rash | 1.0 % | + |
| Hyperprolactinemia | 1.0 % | + |
| Dizziness | 1.0 % | + |
| Dystonia | 1.0 % | + |
| Insomnia | 1.0 % | + |
| Agranulocytosis | 0.0 % | 0.0 |
| Jaundice | 0.0 % | 0.0 |
Tabular extract of the most common side effects
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure
Neurological
Neuroleptic malignant syndrome: alimemazin
Limitations
Based on your
References
No literature information available.
